Best Peptides for Fat Loss and Metabolic Health

Peptides don’t burn fat through a single pathway, and that’s exactly what makes them interesting. Depending on the class, they can suppress appetite, stimulate lipolysis directly in adipose tissue, raise growth hormone output to shift the body toward fat oxidation, improve insulin sensitivity, or enhance mitochondrial efficiency at the cellular level. The best protocols layer complementary mechanisms rather than relying on a single agent.

The landscape has also matured considerably. The clinical success of GLP-1 agonists like semaglutide and tirzepatide has lent real credibility to the broader peptide space. What was once dismissed as fringe medicine is now backed by phase 3 trial data, peer-reviewed meta-analyses, and mainstream clinical adoption.

This guide covers the full spectrum: the pharmaceutical-grade GLP-1 agonists dominating headlines, the growth hormone secretagogue stacks used at peptide clinics, targeted fat-fragment peptides, and the more cutting-edge metabolic compounds gaining traction in the research and biohacking communities.

Tier 1: GLP-1 Agonists – The Most Clinically Proven Fat Loss Agents

Semaglutide (Ozempic / Wegovy)

Semaglutide works by slowing gastric emptying, suppressing appetite at the hypothalamic level, and improving insulin sensitivity. It became the reference standard for pharmaceutical weight loss and remains the most prescribed option globally. In the STEP trials, participants achieved roughly 14.9% body weight reduction over 68 weeks — at the time, the largest efficacy ever demonstrated for an obesity medication.

Real-world experience mirrors the trial data closely. Community consensus consistently describes appetite suppression as the dominant effect, often called the “food noise going quiet.” Side effects (nausea, constipation, occasional vomiting) are the most common reason for titration slowdowns, affecting roughly 14% of users in controlled trials versus 2% on placebo.

• Mechanism: GLP-1 receptor agonist; suppresses appetite, slows gastric emptying, improves insulin sensitivity.
• Clinical evidence: ~14.9% body weight reduction over 68 weeks (STEP trials). Additional cardiovascular risk reduction data from the SELECT trial adds a meaningful longevity argument beyond fat loss alone.
• Best for: A strong first-line GLP-1 option, particularly for those whose prescribers haven’t yet moved to tirzepatide, or where cost and access remain a factor.

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide was where the GLP-1 class made its first major leap. Unlike semaglutide, it’s a dual agonist — activating both GLP-1 and GIP receptors simultaneously. The additional GIP mechanism improves insulin secretion, reduces glucagon, and appears to enhance tolerability, which may explain why tirzepatide users often report fewer GI side effects at equivalent efficacy.

The clinical data is unambiguous. The SURMOUNT-5 head-to-head trial showed tirzepatide delivering 20.2% average body weight reduction at 72 weeks versus semaglutide’s 13.7%. A 2025 meta-analysis of 28,980 participants across seven direct comparative studies confirmed tirzepatide’s superiority, and real-world retrospective data from over 41,000 U.S. adults found 81.8% of tirzepatide users hit the 5% weight loss threshold versus 66.5% on semaglutide.

• Mechanism: Dual GLP-1 and GIP receptor agonist; combines appetite suppression with improved insulin and glucagon regulation.
• Clinical evidence: 20.2% body weight reduction versus semaglutide’s 13.7% in the head-to-head SURMOUNT-5 trial. Superior across all weight loss milestones in real-world data.
• Best for: The current clinical standard. The obvious upgrade from semaglutide for anyone who can access it, and the most common prescription at serious metabolic health clinics today.

Retatrutide – The Triple Agonist Frontier

Retatrutide is Eli Lilly’s next-generation compound — a single molecule activating GLP-1, GIP, and glucagon receptors simultaneously (the “triple G” mechanism). The glucagon component is the key differentiator. Where semaglutide and tirzepatide work primarily through appetite suppression and insulin regulation, glucagon receptor activation directly increases energy expenditure and drives thermogenesis, adding an entirely new fat-burning pathway to the equation.

The Phase 3 TRIUMPH-4 results, released December 2025, were genuinely landmark. At the highest dose over 68 weeks, participants lost an average of 28.7% of body weight (roughly 71 lbs). Visceral fat showed significant preferential reduction, which is particularly relevant for anyone on TRT or an optimized hormone protocol where deep abdominal fat is often the last to move. Regulatory approval is projected for 2027. Retatrutide is not yet legally available outside Lilly’s clinical trials, though compound pharmacy versions have begun appearing.

• Mechanism: Triple GLP-1, GIP, and glucagon receptor agonist; adds thermogenesis and direct energy expenditure to the dual agonist model.
• Clinical evidence: 28.7% average body weight reduction at 68 weeks (TRIUMPH-4, Phase 3). Approximately 42% more effective than tirzepatide’s best data. Significant visceral fat reduction as a secondary outcome.
• Best for: The one to watch. For people who have plateaued on tirzepatide, or who are managing significant visceral adiposity alongside a hormone protocol, it represents a meaningful step up once clean access is established.

Tier 2: Growth Hormone Secretagogues – The Body Composition Stack

CJC-1295 + Ipamorelin

This combination is the most widely used GH peptide stack in anti-aging and performance medicine. CJC-1295 is a GHRH analog that increases the amplitude of GH pulses, while ipamorelin is a selective ghrelin mimetic that increases pulse frequency without meaningfully raising cortisol or prolactin. Together, they produce synergistic GH release that closely mimics the body’s natural pulsatile pattern, without the unwanted hormonal side effects of older GHRPs like GHRP-6.

The fat loss mechanism here is fundamentally different from GLP-1 agents. Elevated GH drives lipolysis directly (breakdown of stored triglycerides into free fatty acids), shifting substrate utilization toward fat oxidation. A 2024 prospective study in adults aged 40–65 (n=48, 12 months) showed 10–15% reductions in visceral fat alongside modest lean mass gains. Results are gradual and cumulative rather than dramatic, which community experience on r/Peptides reflects consistently.

• Mechanism: GHRH analog (CJC-1295) combined with a selective GHRP (ipamorelin); synergistic GH release drives lipolysis and lean mass preservation.
• Clinical evidence: 10–15% visceral fat reduction over 6–12 months in prospective data. A 2025 RCT also demonstrated a 23% increase in slow-wave sleep, which has meaningful downstream implications for GH output and recovery.
• Dosing (typical clinic protocol): 100–300mcg ipamorelin and 100–200mcg CJC-1295 (no DAC), subcutaneously, 5 days on / 2 days off. Bedtime dosing is preferred to amplify the natural overnight GH pulse.
• Best for: Body recomposition rather than purely scale weight loss. Also valuable as an adjunct to GLP-1 therapy to preserve muscle mass during aggressive fat loss phases.

Tesamorelin

Tesamorelin is a stabilized synthetic GHRH analog and the only FDA-approved peptide in this class (approved for HIV-associated lipodystrophy). That approval gives it a clinical data floor most peptide clinic offerings lack. In the lipodystrophy trials, tesamorelin reduced trunk and visceral fat by approximately 18% compared to placebo. Off-label use for abdominal fat reduction in general populations has grown substantially, particularly as compound pharmacies have made it accessible through metabolic health and TRT clinics.

What distinguishes tesamorelin from the ipamorelin/CJC-1295 stack is its more targeted effect on visceral fat specifically. The GH it stimulates is particularly effective at mobilizing the deep abdominal depot, which is both the most metabolically harmful and often the most resistant to conventional diet and exercise. IGF-1 levels rise with use, warranting monitoring in a clinical setting.

• Mechanism: Synthetic GHRH analog; stimulates endogenous GH release with preferential effect on visceral and abdominal fat mobilization.
• Clinical evidence: ~18% trunk fat reduction in FDA approval trials. The only peptide in this class with a full regulatory data package.
• Best for: Patients specifically targeting visceral and abdominal fat. Frequently layered with CJC-1295/ipamorelin in clinic stacks to cover both visceral-targeted and systemic GH optimization.

Tier 3: Targeted Fat-Fragment Peptides

AOD-9604 (HGH Fragment 177-191)

AOD-9604 is a synthetic fragment of human growth hormone (amino acids 177–191, with an added tyrosine residue for stability). It retains the lipolytic region of the GH molecule while omitting the growth-promoting portion entirely. The result is direct stimulation of lipolysis and inhibition of lipogenesis (fat storage), without affecting IGF-1 levels, blood glucose, or producing the acromegalic effects associated with exogenous HGH.

Preclinical data in obese animal models demonstrated meaningful body fat reduction without changes to food intake, pointing to a direct lipolytic mechanism rather than an appetite or GH-mediated effect. There are no large-scale human RCTs, so the evidence base remains primarily preclinical and observational. Community experience positions AOD-9604 as an effective adjunct rather than a standalone, commonly stacked with ipamorelin/CJC-1295 or layered onto GLP-1 therapy to accelerate localized fat mobilization.

• Mechanism: HGH fragment that stimulates lipolysis and inhibits lipogenesis directly, without IGF-1 elevation or anabolic effects.
• Clinical evidence: Primarily preclinical (Heffernan et al.); robust fat mass reduction in obese animal models without food intake changes. Limited human data.
• Dosing (typical): 300–500mcg subcutaneously, fasted in the morning, 5 days on / 2 days off.
• Best for: A targeted fat mobilizer within a broader stack. Particularly useful for stubborn fat deposits, or as a complement to GLP-1 therapy to accelerate adipose reduction alongside scale weight loss.

Tier 4: Emerging Metabolic Agents

MOTS-c

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a mitochondrial-derived peptide first characterized by Lee et al. in 2015. It activates the AMPK signaling pathway (essentially a master switch for cellular energy balance) and has been described by researchers as a potential “exercise mimetic” for its ability to enhance fatty acid oxidation in skeletal muscle and improve glucose uptake independently of insulin signaling. In high-fat diet murine models, MOTS-c administration prevented diet-induced obesity and improved insulin sensitivity.

The 2025–2026 research wave has expanded into MOTS-c’s role in age-related metabolic decline, making it increasingly relevant to the longevity and performance medicine space. Community discussions position it primarily as a metabolic optimizer and stack component rather than a primary fat loss driver.

• Mechanism: Mitochondrial-derived peptide; AMPK activation, enhanced fatty acid oxidation, improved glucose uptake independent of insulin.
• Clinical evidence: Largely preclinical. Strong mechanistic data in murine models; expanding human research focused on metabolic aging and exercise performance.
• Best for: Advanced peptide users focused on metabolic optimization beyond weight loss — insulin sensitivity, mitochondrial function, and exercise capacity. Most commonly stacked with tesamorelin, ipamorelin, or GLP-1 agents.

5-Amino-1MQ (NNMT Inhibitor)

5-Amino-1MQ is one of the more mechanistically distinct compounds in the fat loss space. Technically a small synthetic molecule rather than a traditional peptide, it’s commonly grouped with peptide protocols given where it’s prescribed and how it’s used. It specifically inhibits NNMT (nicotinamide N-methyltransferase), an enzyme expressed at high levels in adipose tissue that, when overactive, suppresses NAD+ availability and pushes cells toward fat storage and reduced energy expenditure. It was first characterized by researchers at the University of Texas Medical Branch in 2017.

In vitro studies showed 5-Amino-1MQ increased intracellular NAD+ and suppressed lipogenesis in adipocytes. In vivo, treated mice showed significantly reduced body weight, white adipose mass, and adipocyte size — without changes to food intake. A 2024 paper in Scientific Reports further demonstrated that combining 5-Amino-1MQ with exercise improved grip strength and sustained running performance beyond exercise alone, suggesting meaningful muscle-sparing and mitochondrial benefits alongside the fat loss signal.

• Mechanism: NNMT inhibitor; preserves NAD+ availability, suppresses lipogenesis, and shifts cells toward fat oxidation without appetite suppression.
• Clinical evidence: Strong preclinical data (UTMB research group); fat cell size reduced 30–40% in adipocyte models without dietary changes. 2024 Scientific Reports data on muscle performance and exercise capacity. Human trial data remains limited.
• Best for: People who are metabolically optimized on paper but feel fat loss has stalled — particularly those with pre-diabetic markers, elevated metabolic age, or evidence of cellular energy dysregulation. Increasingly discussed as a GLP-1 companion compound to preserve NAD+ and mitochondrial function during aggressive caloric restriction.

How the Pieces Fit Together

The most effective real-world protocols layer mechanisms rather than relying on a single agent. A GLP-1 agent handles appetite and insulin regulation. A GH secretagogue stack (CJC-1295/ipamorelin, with or without tesamorelin) handles lipolysis and lean mass preservation. AOD-9604 adds direct fat mobilization. Metabolic optimizers like MOTS-c or 5-Amino-1MQ address cellular efficiency and NAD+ depletion that often accompanies aggressive fat loss protocols.

GLP-1 agents are the most powerful drivers of scale weight loss. The GH secretagogue stack is the most important for maintaining body composition quality, ensuring what’s lost is fat rather than muscle. The targeted and emerging agents play supporting roles — but meaningful ones for those building a comprehensive protocol.

Bloodwork matters throughout. IGF-1, fasting insulin, HbA1c, lipids, and a comprehensive metabolic panel should be baseline markers before starting and monitored on-cycle. Clinics running serious protocols will require this, and those that don’t are worth treating with skepticism.

FAQs